SCHEMBL2885503

SCHEMBL2885503

COc1ccc(-c2n[nH]c(=O)c3cnccc23)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNE2 O96020 2/20 0.56
CDK4 P11802 2/20 0.56
CCND1 P24385 2/20 0.56
CCNE1 P24864 2/20 0.56
CDK2 P24941 2/20 0.56
GSK3A P49840 3/20 0.50
GSK3B P49841 3/20 0.50
DYRK1A Q13627 2/20 0.50
ENPP1 P22413 1/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
MAPK1 P28482 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ROCK1 Q13464 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30719652 0.82 ATM (0.67) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL710318 0.82 ATM (0.67) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL4124300 0.81 ENPP1 (0.66) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL4837386 0.77 ENPP1 (0.56) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL25184550 0.77 GSK3A (0.55) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL4834774 0.76 ENPP1 (0.55) CDK4CCND1GSK3AGSK3BDYRK1A
SCHEMBL1789703 0.76 ENPP1 (0.55) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL4839229 0.76 KDM4E (0.56) GSK3AGSK3BDYRK1AENPP1KDM4E
Hydrochloric Acid SCHEMBL25180503 0.75 GSK3A (0.54) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL2887372 0.75 KDM4E (0.54) CCNE2CDK4CCND1CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645756-B2 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases BANYU PHARMACEUTICAL CO. LTD. (JP) 2010-01-12 US disclosed
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative MSD K.K. (JP) 2007-07-19 US disclosed
EP-1719756-A1 NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative HRH3, HRH2, HRH4 CCNE2 1072/4885CDK4 3621/4885CCND1 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.